根治性膀胱切除加尿流改道术后骨折风险与骨特异性药物治疗的启动
结论支持加强此类患者骨健康关注。
要点
- 根治性膀胱切除加尿流改道患者骨折累积发生率高于一般人群匹配对照。
- 女性股骨骨折HR 1.97(95%CI 1.25-3.10)、任何骨折HR 2.06(95%CI 1.54-2.76)。
- 男性任何骨折HR 1.51(95%CI 1.22-1.88),骨特异性药物启动无差异。
核心结论
- 根治性膀胱切除加尿流改道与骨折风险增加相关,尤其女性。
- 附加分析提示骨折风险可能受膀胱癌及其治疗相关因素影响,但最强且最一致的关联见于根治性膀胱切除加尿流改道后。
- 研究结果支持对此类患者增加骨健康关注。
研究设计与样本
- 采用竞争风险分析估计累积发生率,使用按性别分层的多变量Cox模型得出风险比。
- 附加分析纳入328例接受治愈性放疗的肌层浸润性膀胱癌患者。
主要发现
- 与对照者相比,根治性膀胱切除加尿流改道与更高的骨折累积发生率相关。
- 女性股骨骨折风险增加(HR 1.97,95%CI 1.25-3.10),任何骨折风险增加(HR 2.06,95%CI 1.54-2.76)。
- 男性任何骨折风险增加(HR 1.51,95%CI 1.22-1.88)。
- 两性中骨特异性药物治疗的启动均未观察到关联。
- 附加队列中,接受放疗的男性任何骨折风险增加(HR 2.14,95%CI 1.26-3.62),女性估计不精确。
临床怎么用
- 对根治性膀胱切除加尿流改道患者,尤其女性,应关注骨健康并评估骨折风险。
- 男性患者同样需注意任何骨折风险增加,但骨特异性药物启动情况无差异需进一步研究。
局限性
- 附加放疗队列中女性骨折风险估计不精确。
- 骨特异性药物治疗启动无关联,可能受限于未测量的混杂因素或随访因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the risk of fractures among patients with bladder cancer who underwent radical cystectomy (RC) with urinary diversion (UD), compared with matched referents from the general population. PATIENTS/SUBJECTS AND METHODS: We identified 2908 patients who underwent RC between 2011 and 2019, and 13 669 matched referents in a nationwide, register-based Swedish cohort study. Outcomes were femoral fracture, any fracture, and initiation of bone-specific drug therapy (BDT). Cumulative incidence was estimated using competing-risk analyses, and hazard ratios (HRs) were derived from multivariable Cox models stratified by sex. Additional analyses were conducted among patients with muscle-invasive bladder cancer treated with curative radiotherapy (n = 328). RESULTS: Compared to referents, RC with UD was associated with a higher cumulative incidence of fractures. Women had an increased risk of femoral fracture (HR 1.97, 95% confidence interval [CI] 1.25-3.10) and any fracture (HR 2.06, 95% CI 1.54-2.76), while men had an increased risk of any fracture (HR 1.51, 95% CI 1.22-1.88). No association was observed for initiation of BDT in either sex. In the additional cohort, men treated with radiotherapy had an increased risk of any fracture (HR 2.14, 95% CI 1.26-3.62), whereas estimates for women were imprecise. CONCLUSION: Patients undergoing RC with UD experienced increased fracture risks, particularly women. Additional analyses suggest that fracture risk may be influenced by factors related to both bladder cancer and its treatment, although the strongest and most consistent associations were observed following RC with UD. These findings support increased attention to bone health in these patients.
引用
- Van Hemelrijck M, Holmberg L, Garmo H, et al. Fracture risk and initiation of bone-specific drug therapy following radical cystectomy with urinary diversion. BJU Int. 2026. PMID: 42847568. doi:10.1111/bju.70472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。